Ariana Pelosci, associate editor for CancerNetwork®, has been with the team since June 2021. She specializes both in web and print, and runs the social media for CancerNetwork®.
She is a graduate of the University of Delaware, where she studied Media Communications and minored in journalism and marketing. At heart, she is a Jersey girl, and you can always find her down the shore during her free time.
Ariana loves to read, specifically historical or contemporary fiction. Follow Ariana on Twitter @APelosci or email her at apelosci@mjhlifesciences.com.
Ponatinib Combo Demonstrates Superiority Vs Imatinib in Ph+ Leukemia Subtype
February 16th 2023An expert from the University of Texas MD Anderson Cancer Center says that ponatinib plus reduced-intensity chemotherapy may be a new standard of care for frontline Philadelphia chromosome–positive acute lymphoblastic leukemia.
ODAC Votes 8-5 in Favor of Dostarlimab Trial in Advanced Rectal Cancer
February 9th 2023In a meeting with the FDA’s Oncologic Drugs Advisory Committee experts discussed findings that have read out with regard to dostarlimab for patients with mismatch repair deficiency/microsatellite instability–high locally advanced rectal cancer.
FDA Approves Sacituzumab Govitecan-hziy in Pre-Treated HR+/HER2– Advanced Breast Cancer
February 3rd 2023Patients with pre-treated, unresectable locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer can now receive treatment with sacituzumab govitecan following approval from the FDA.
Updated Capecitabine Approval Ignites ‘Broad Impact’ in Cancer Under New FDA Program
January 23rd 2023Under a new FDA initiative, the agency recently updated a decades’ old approval of the chemotherapy capecitabine. This move, according to an expert, will springboard further change in the treatment of cancer.
Lenalidomide Plus Rituximab Improved PFS in 5-Year Follow-Up for R/R Indolent Non-Hodgkin Lymphoma
December 10th 2022The 5-year follow-up of the phase 3 AUGMENT trial produced enhanced progression-free survival when lenalidomide plus rituximab was used to treat patients with relapsed/refractory indolent non-Hodgkin lymphoma.
Capivasertib Plus Fulvestrant Yields PFS Improvement in HR+/HER2– Breast Cancer
December 8th 2022Results from the phase 3 CAPItello-291 trial indicated that the combination of capivasertib plus fulvestrant produced improved progression-free survival in patients who have hormone-receptor–positive/HER2-negative advanced breast cancer.
Vaccine-Chemoradiotherapy Combo Produces 100% Clinical Response in Advanced Cervical Cancer
November 15th 2022Results from the ongoing phase 2 IMMUNOCERV trial showed that treatment with the investigational drug PDS0101 — a vaccine — combined with chemotherapy and radiation induced a 100% clinical response in a small group of patients with stage IB3 to IVA cervical cancer.
Plant-Based Diet, Stool Butyrate Associated with Long-Lasting MRD Negativity in Multiple Myeloma
November 14th 2022Data from a study indicated that durable minimal residual disease negativity was associated with stool butyrate production in patients with multiple myeloma who had plant-based diets undergoing treatment with lenalidomide maintenance.
Rare Pediatric Designation Granted by the FDA to Nomacopan for HSCT Thrombotic Microangiopathy
November 10th 2022Findings from a phase 3 trial assessing nomacopan in patients with hematopoietic stem cell transplant–related thrombotic microangiopathy helped to support a rare pediatric designation from the FDA for the agent.
Trilaciclib Prior to Sacituzumab Govitecan-hziy Appeared to Reduce AEs in Advanced TNBC
November 3rd 2022Initial findings from a phase 2 trial showed trilaciclib given before sacituzumab govitecan-hziy lessened the severity of adverse effects in patients with unresectable locally advanced or metastatic triple-negative breast cancer.